Solutions

Abstract

In this appendix, the details regarding the requirements for the proof of additional benefit, for the determination of the appropriate comparator and for the dossier submitted by the pharmaceutical company are outlined. Which studies are to be submitted by the pharmaceutical entrepreneur in the AMNOG dossier is also regulated: In the dossier, the G-BA must be provided with the clinical study reports of the pivotal studies including the study protocols and the assessment report of the regulatory authority. The Assessment of the AMNOG Dossier by the G-BA and the Impact After three months, the reimbursement authorities' assessment of the dossier is published and the manufacturer now has the opportunity to respond to the assessment. If this recognizes an additional therapeutic benefit compared to the standard therapy, the GKV-Spitzenverband (the umbrella organization of the German statutory health insurance funds) and the manufacturer negotiate the price at which the drug will be reimbursed by the statutory health insurance funds.

Abstract

Continuing to recognise devices in this way will help maintain safe, uninterrupted access to the treatments and technologies that patients and the NHS rely on, the government stated. Meanwhile, indefinite recognition of the CE mark fits alongside the UKCA marking route, which continues to operate as the domestic approval pathway for devices placed on the market in Britain, it added. Tallon added that the MHRA will continue to oversee the safety of every device on the UK market, and remains committed to working closely with international partners to identify and act on safety concerns quickly." Following the UK's departure from the European Union in 2016, as a means of moving away from European legislation, makers of devices or IVDs already bearing a CE-mark were given a timeline to transition to the UK's own UKCA regime to continue marketing their products in the UK. Under the original plans, makers of medical devices CE-marked under the old European medical devices directive (EU MDD) or EU active implantable medical devices directive (EU AIMDD) could be placed on the British market until 30 June 2028, with the same cutoff for IVDs tagged under the previous EU regulatory regime."

Abstract

A laboratory result can identify an unwanted substance in food without answering the question that matters most to a producer: what should happen to the batch? That decision depends on the substance, its concentration, the reliability of the measurement, the intended consumer and the applicable rules. A traceability project could measure the time required to reconstruct a batch's route, the proportion of records that can be matched and the precision of a simulated withdrawal. An alert system is also a learning system The EU's Rapid Alert System for Food and Feed enables authorities to exchange information about health risks and coordinate action.

Abstract

Decades of male-focused studies, combined with lower awareness of heart attack symptoms in women, have contributed to the poorer outcomes we see today," said Karen Padilla, who leads the Women & Heart Patient Network at the Global Heart Hub, the first global umbrella organisation for cardiovascular patient groups. The READI project is looking at the barriers that prevent some people (women, people with disabilities, ethnic minorities, rural communities and older adults) from accessing and participating in clinical research and what can be done to make it easier for them to take part and stay involved. "As a result, some of the very people who stand to benefit most from advances in medicine are less likely to be represented in the research that underpins them." Borobia points to a recent heart failure trial in which the average participant was 67 years old and more than 60% were male. "If a drug reaches market and unexpected adverse events emerge because certain populations were under-represented in trials, no one benefits." Where previously certain groups, such as women, were often excluded because the perceived risk was too high, the new approach is to put appropriate safeguards in place, assess the risks properly and make inclusion the starting point of research, she explained."

Abstract

OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development.OpenAI is bringing Orchestra's team and technology together with Rosalind, the AI models and tools for life sciences research. Together, they aim to build agents that help teams connect scientific findings with the studies, decisions, and next steps needed to advance a potential medicine. Scientists and program leaders delegate the monitoring and tracking of studies and campaigns to agents, freeing up time to guide the work, make decisions, and address issues before they cause delays. OpenAI's vision is for AI to help scientists across the full process of discovering and developing new medicines: exploring ideas, designing experiments, interpreting results, and coordinating the work needed to advance promising treatments.